These groundbreaking Alzheimer’s drugs slow brain decline by treating the actual cause of dementia

Two new groundbreaking drugs could slow the memory impairment, thinking skills and overall brain decline — and both are ...
Morningstar

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"

TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters ...
WebMD

FDA Approves At-Home Once-Weekly Leqembi Injection as Maintenance Therapy for Early Alzheimer's Disease

Leqembi (lecanemab-irmb) is a prescription medicine approved to treat early stages of Alzheimer's disease, such as mild cognitive impairment or mild dementia. The recent FDA approval of Leqembi IQLIK ...
Nasdaq

Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector

Biogen Inc.’s BIIB Japan-based partner, Eisai., announced that it has initiated the rolling submission of a biologics license application (“BLA”) to the FDA seeking approval for Leqembi (lecanemab) ...
Nasdaq

Eisai Begins Rolling SBLA Submission For LEQEMBI IQLIK Subcutaneous Autoinjector

(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK) and Biogen Inc. (BIIB) announced that Eisai has initiated the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S.